Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor

Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35 Keyan Rd., Zhu Nan Town, Miaoli County 350, Taiwan, ROC.
Biochemical pharmacology (Impact Factor: 4.65). 05/2009; 78(2):203-10. DOI: 10.1016/j.bcp.2009.03.032
Source: PubMed

ABSTRACT DPP-IV (EC is a validated drug target for human type II diabetes. DPP-IV inhibitors without DPP8/9 inhibitory activity have been sought because a possible association has been reported between a "DPP8/9 inhibitor" and severe toxicity in animals. However, at present, it is not known whether the observed toxicity is associated with DPP8/9 inhibition, or an off-target effect induced by the compound. We investigated whether the inhibition of DPP8/9 is the cause of the severe toxicity in animals using a very potent and selective DPP8/9 inhibitor with different pharmacophore, 1G244. By Ki measurement, 1G244 is 15- and 8-fold more potent against DPP8 and DPP9, respectively, than the "DPP8/9 inhibitor". Strikingly, the "DPP8/9 inhibitor" does not penetrate the plasma membrane but remains outside the cells, whereas 1G244 readily enters the cells, even at low doses. By repeatedly exposing Sprague-Dawley rats to 1G244 by intravenous injection for a period of 14 days, we observed no significant toxicological symptoms associated with 1G244. Blood and serum chemistry parameters were all within the normal ranges for the treated animals. Because of the high potency, good membrane penetration and adequate tissue distribution of 1G244, the mild symptoms observed are probably associated with DPP8/9 inhibition.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Dipeptidyl peptidase IV (DPP-IV) deactivates the natural hypoglycemic incretin hormone GLP-1. Inhibition of this enzyme restores glucose homeostasis in diabetic patients making it an attractive target for the development of new antidiabetic drugs. With this in mind, we suggested an in silico work flow for the identification of novel DPP-IV inhibitors. Ligand-based and structure-based pharmacophores were designed using HipHop program provided in catalyst and ligandScout 3.0 software, respectively. Generated models were validated by receiver operating characteristic curve analysis, Guner–Henry scoring method and by pharmacophore-based screening of marketed DPP-IV inhibitors. Ligand-based pharmacophore model A scored 0.8 AUC value, 0.865 Guner–Henry score and gave all marketed DPP-IV inhibitors as hits through screening while structure-based pharmacophore B scored 0.77 AUC value, 0.66 Guner–Henry score and gave four marketed DPP-IV inhibitors as hits (except alogliptin) out of five. These validated pharmacophores have effectively been used in search of three databases, Maybridge hitfinder collection, Chemdiv, and Asinex. Resulting hits were subjected to molecular docking using ligandfit program. Five hit compounds namely Asinex ASN 09417841, AW 00785, ChemDiv 0173-0023, ChemDiv 0276-0112, and ChemDiv 8010-1357 scored high Ligscore1 and −PLP1 score comparable to standard drug sitagliptin. Good interactions were found with important residues like Glu205, Glu206, Tyr662, Phe357, Arg358, Tyr666 etc. They were reported as novel virtual leads to design potent DPP-IV inhibitors.
    Medicinal Chemistry Research 09/2013; 22(9). DOI:10.1007/s00044-012-0455-6 · 1.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Protein degradation is an essential process that continuously takes place in all living cells. Regulated degradation of most cellular proteins is initiated by proteasomes, which produce peptides of varying length. These peptides are rapidly cleaved to single amino acids by cytoplasmic peptidases. Proline-containing peptides pose a specific problem due to structural constrains imposed by the pyrrolidine ring that prevents most peptidases from cleavage. Here we show that DPP9, a poorly characterized cytoplasmic prolyl-peptidase, is rate-limiting for destruction of proline-containing substrates both in cell extracts and in intact cells. We identified the first natural substrate for DPP9, the RU1(34-42) antigenic peptide (VPYGSFKHV). RU1(34-42) is degraded in vitro by DPP9, and down-regulation of DPP9 in intact cells results in increased presentation of this antigen. Together our findings demonstrate an important role for DPP9 in peptide turnover and antigen presentation.
    Journal of Biological Chemistry 09/2009; 284(40):27211-9. DOI:10.1074/jbc.M109.041871 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: For a series of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV ADME properties were improved by the incorporation of amide replacements. These efforts led to a novel series of potent and selective inhibitors of DPP-4 that exhibit an attractive pharmacokinetic profile and show excellent efficacy in an animal model of diabetes.
    Bioorganic & medicinal chemistry letters 11/2009; 19(22):6340-5. DOI:10.1016/j.bmcl.2009.09.078 · 2.33 Impact Factor